LAVA Medtech Acquisition Corp. financial data

Industry
Blank Checks
Location
303 Wyman St Ste 300, Waltham, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2022 - Mar 30, 2023

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 112 %
Debt-to-equity -150 %
Return On Equity -117 %
Return On Assets 3.75 %

Shares

Label TTM Value / Value Unit Change %
Entity Public Float 115M USD

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 1.3M USD
Nonoperating Income (Expense) 6.37M USD
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 4.81M USD
Income Tax Expense (Benefit) 304K USD
Net Income (Loss) Attributable to Parent 4.5M USD

Balance Sheet

Label TTM Value / Value Unit Change %
Assets, Current 1.37M USD -37.9%
Deferred Income Tax Assets, Net 19.2K USD
Assets 121M USD +0.31%
Accounts Payable, Current 221K USD +717%
Liabilities, Current 4.76M USD +3555%
Liabilities 4.76M USD -46.5%
Retained Earnings (Accumulated Deficit) -3.01M USD +53.5%
Stockholders' Equity Attributable to Parent -3.01M USD +53.5%
Liabilities and Equity 121M USD +0.31%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -207K USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 1.16M USD -24.8%
Deferred Tax Assets, Valuation Allowance 316K USD +636%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure
Deferred Tax Assets, Gross 316K USD +409%
Deferred Income Tax Expense (Benefit) 9.09K USD
Preferred Stock, Shares Authorized 1M shares 0%
Current Federal Tax Expense (Benefit) 1 USD
Deferred Tax Assets, Net of Valuation Allowance 28.2K USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%